Prognostic Potential of Secreted Modular Calcium-Binding Protein 1 in Low-Grade Glioma

Wang, Jing; Xia, Shu; Zhao, Jing; Chen, Gong; Xi, Qingsong; Sun, Wei

doi:10.3389/fmolb.2021.666623

Cited by 9 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these markers, 15 were PDR-based markers, 8 AMF-based markers, 10 MHL-based markers, 5 UMHL-based markers, 6 MHL3-based markers, and 16 UMHL3-based markers. These 60 MHB markers were annotated to 58 genes, and notably, 18 of these genes have previously reported to be associated with thyroid dysfunction or thyroid diseases, and 27 were involved in immune regulation (Additional file 1 : Table S2 [ 28 – 94 ]).…”

Section: Resultsmentioning

confidence: 99%

Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study

Wang,

Zhao,

et al. 2024

BMC Med

View full text Add to dashboard Cite

Background Thyroid nodule (TN) patients in China are subject to overdiagnosis and overtreatment. The implementation of existing technologies such as thyroid ultrasonography has indeed contributed to the improved diagnostic accuracy of TNs. However, a significant issue persists, where many patients undergo unnecessary biopsies, and patients with malignant thyroid nodules (MTNs) are advised to undergo surgery therapy. Methods This study included a total of 293 patients diagnosed with TNs. Differential methylation haplotype blocks (MHBs) in blood leukocytes between MTNs and benign thyroid nodules (BTNs) were detected using reduced representation bisulfite sequencing (RRBS). Subsequently, an artificial intelligence blood leukocyte DNA methylation (BLDM) model was designed to optimize the management and treatment of patients with TNs for more effective outcomes. Results The DNA methylation profiles of peripheral blood leukocytes exhibited distinctions between MTNs and BTNs. The BLDM model we developed for diagnosing TNs achieved an area under the curve (AUC) of 0.858 in the validation cohort and 0.863 in the independent test cohort. Its specificity reached 90.91% and 88.68% in the validation and independent test cohorts, respectively, outperforming the specificity of ultrasonography (43.64% in the validation cohort and 47.17% in the independent test cohort), albeit with a slightly lower sensitivity (83.33% in the validation cohort and 82.86% in the independent test cohort) compared to ultrasonography (97.62% in the validation cohort and 100.00% in the independent test cohort). The BLDM model could correctly identify 89.83% patients whose nodules were suspected malignant by ultrasonography but finally histological benign. In micronodules, the model displayed higher specificity (93.33% in the validation cohort and 92.00% in the independent test cohort) and accuracy (88.24% in the validation cohort and 87.50% in the independent test cohort) for diagnosing TNs. This performance surpassed the specificity and accuracy observed with ultrasonography. A TN diagnostic and treatment framework that prioritizes patients is provided, with fine-needle aspiration (FNA) biopsy performed only on patients with indications of MTNs in both BLDM and ultrasonography results, thus avoiding unnecessary biopsies. Conclusions This is the first study to demonstrate the potential of non-invasive blood leukocytes in diagnosing TNs, thereby making TN diagnosis and treatment more efficient in China.

show abstract

Section: Resultsmentioning

confidence: 99%

Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study

Wang,

Zhao,

et al. 2024

BMC Med

View full text Add to dashboard Cite

show abstract

“…Among these genes, higher expression of SMOC1 correlated positively with a better prognosis in glioma patients. Wang et al also reported that SMOC1 was upregulated in low-grade gliomas (LGGs) and that higher SMOC1 expression correlated with a better prognosis in LGG patients [24]. Interestingly, SMOC1 expression correlated negatively with in ltration by B cells, CD4 + T cells, CD8 + T cells, macrophages and dendritic cells in LGGs, suggesting that SMOC1 may be associated with the tumor microenvironment of glioma [24].…”

Section: Discussionmentioning

confidence: 97%

Downregulation of SMOC1 is associated with progression of colorectal traditional serrated adenomas

Aoki,

Takasawa,

Yamamoto

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Aberrant DNA methylation is prevalent in colorectal serrated lesions. We previously reported that the CpG island of SMOC1 is frequently methylated in traditional serrated adenomas (TSAs) and colorectal cancers (CRCs) but is rarely methylated in sessile serrated lesions (SSLs). In the present study, we aimed to further characterize the expression of SMOC1 in early colorectal lesions. Methods SMOC1 expression was analyzed immunohistochemically in a series of colorectal tumors (training set, n = 126; validation set, n = 73) and adjacent normal colonic tissues (n = 112). Results Mean immunohistochemistry scores in normal colonic tissues and tumors in a training set were as follows: normal colon, 24.2; hyperplastic polyp (HP), 21.6; SSL, 24.8; SSL with dysplasia (SSLD)/SSL with early invasive cancer (EIC), 17.5; TSA, 7.3; low grade adenoma, 21.4; high grade adenoma, 11.7; high grade dysplasia (HGD), 12.1; EIC, 10.9. Abundant expression of SMOC1 in SSLs and significant downregulation of SMOC1 in TSAs were further confirmed in a validation set. Higher levels SMOC1 expression correlated positively with proximal colon locations and flat tumoral morphology, reflecting its abundant expression in SSLs. Among TSAs that contained both flat and protruding components, levels of SMOC1 expression were significantly lower in the protruding components. Conclusion Our results suggest that reduced expression of SMOC1 is associated with progression of TSAs and conventional adenomas and that SMOC1 may be a biomarker for diagnosis of serrated lesions and risk prediction in colorectal tumors.

show abstract

“…SMOC1 in particular is a promising target as it acts downstream of RUNX2, a known master regulator of osteogenesis. While therapeutic upregulation of RUNX2 raises concerns regarding potential adverse effects including increased cancer and osteoarthritis risk [42,43], SMOC1 expression is instead associated with more favourable cancer outcomes [44,45]. Similarly to RUNX2, oncogenic properties are also described for other previously identified genes, e.g., EFNB2 [46].…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cells from people with osteoporosis are fewer, and defective in both osteogenic and adipogenic capacity

Cassidy,

Shortiss,

Thompson

et al. 2024

Explor Musculoskeletal Dis

View full text Add to dashboard Cite

Aim: Osteoporosis (OP) is caused by imbalanced bone remodelling homeostasis. It is highly prevalent, especially in post-menopausal women, resulting in high risk of fracture and morbidity. Mesenchymal stromal cells (MSCs) are osteoblast progenitors, and orchestrate the function of surrounding cells including osteoblasts. Understanding MSC phenotype and function is therefore critical in discerning the aetiology of OP and developing superior therapies. Currently, adequate long-term therapeutic strategies are not available. Methods: Bioinformatic analysis of ribonucleic acid sequencing (RNA-seq) data revealed differential expression of genes primarily related to osteogenic differentiation and proliferation, followed by confirmatory in vitro analysis. Results: This study identified novel and previously proposed targets for therapeutic intervention in OP. Functional assessment demonstrated reduced MSC number and osteogenic capacity associated with OP. Proliferation was not affected but OP was unexpectedly associated with a reduction in MSC adipogenic differentiation capacity, correlating with donor age. Conclusions: These data indicate specific targets for further studies of future treatments for OP, including the assessment of modified MSCs as therapeutics. Advances in this area may contribute to reducing fracture-associated morbidity and mortality, and improving quality of life for the 200 million people living with OP globally.

show abstract

Prognostic Potential of Secreted Modular Calcium-Binding Protein 1 in Low-Grade Glioma

Cited by 9 publications

References 44 publications

Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study

Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study

Downregulation of SMOC1 is associated with progression of colorectal traditional serrated adenomas

Mesenchymal stromal cells from people with osteoporosis are fewer, and defective in both osteogenic and adipogenic capacity

Contact Info

Product

Resources

About